Prevalence of heart failure (HF) increases significantly with age, coinciding with age-related changes in body composition that are common and consequential. Still, body composition is rarely factored in routine HF care.
T he nomenclature of heart failure (HF) implies a cardiocentric disease, which has reinforced the prioritization of HF research and therapies premised on ventricular morphological and functional, arrhythmic, hemodynamic, and other central cardiac pathophysiological mechanisms, with relatively less emphasis accorded to peripheral consequences of the disease. 1 Nonetheless, several peripheral manifestations of HF have been identified, including diminished skeletal muscle microvascular architecture and perfusion, 2, 3 as well as altered skeletal muscle histology and bioenergetics with intrinsic weakening. 2, 4 Prevalence of HF increases with age, 5 and implications of peripheral manifestations of HF may be particularly important among older adults as aging is associated with loss of lean body mass 6 and increased fat mass, 7 which in turn impact functional capacity, frailty risk, and general well-being. [8] [9] [10] Focus on body composition in patients with HF is further intensified by a separate consideration of the socalled obesity paradox. Multiple studies highlight risks associated with obesity both in causing and aggravating HF, 11, 12 whereas other studies suggest that once HF occurs, obesity may provide protective life-sustaining benefits. 13, 14 This study uses data from the Health, Aging, and Body Composition (Health ABC) study to analyze body composition trajectories in older adults who developed incident HF. Using yearly dual-energy X-ray absorptiometry (DXA) scans, body composition was assessed serially over 6 years with comparisons of those who developed incident HF to those who did not. We hypothesized that HF would exacerbate the typical age-associated changes in body composition remodeling, that is, that lean body mass would decrease at a greater rate in older adults with HF and fat mass would increase at a greater rate. We also delineated proportions of lean and fat mass in older adults with high body mass index (BMI) who developed HF to clarify relationships that might shed light on the obesity paradox.
SUBJECTS AND METHODS
Health ABC is a prospective cohort study of nondisabled adults with comprehensive assessments that included yearly DXAs for the first 6 years. Using DXA metrics, body composition was compared in participants who developed HF with those who did not. Changes in total body mass, lean mass, and fat mass were each evaluated. The institutional review boards of the University of Pittsburgh, the University of Tennessee, the University of California-San Francisco Coordinating Center, and the National Institute on Aging approved the study, and all participants gave informed consent.
Health ABC
Health ABC enrolled 3075 black (41.7%) and white men and women (51.5%) aged 70 to 79 years between March 1997 and April 1998, who resided in the Memphis, TN, and Pittsburgh, PA, areas. Eligibility criteria included no selfreported difficulty walking a quarter mile, climbing 10 steps, or performing activities of daily living, no reported use of a walking aid, and no active cancer treatment. Exclusion criteria included cognitive impairment and inability to communicate.
DXA scans were performed annually, in all participants, for the first 6 years of the study; thus, we limited the surveillance period to this time frame (1997-1998 and 2002-2003) . Of the 3075 Health ABC study participants, 2815 were eligible for this study; HF cases (n=111) and controls (n=2704). Figure 1 shows the flow of Health ABC participants to the analytic sample. Reasons for exclusion from the final analytic sample were baseline prevalent HF (n=40), no follow-up DXA scans after incident HF (n=38), or after baseline study in the noncases (n=182).
Heart Failure
The primary criterion for incident HF was a hospitalization for a HF event, which was adjudicated at each field center using medical records. Criteria used to diagnose HF included (1) symptoms (eg, shortness of breath, fatigue, orthopnea, or paroxysmal nocturnal dyspnea), (2) physical signs (eg, edema, rales, tachycardia, a gallop rhythm, or a displaced point of maximal impulse), and (3) medical therapy (a diuretic and digitalis or a β-blocker or vasodilator). Although not required, additional supporting evidence included a chest x-ray showing cardiomegaly and pulmonary edema or cardiac imaging (echocardiography or contrast ventriculography) showing evidence of a dilated ventricle and global or segmental wall motion abnormalities with decreased systolic function.
Baseline prevalent HF was defined as a self-reported history of HF confirmed with the usage of diuretic and either vasodilator or cardiac glycoside medications. These Health ABC participants were excluded from this analysis. Among those with incident HF, HF with reduced ejection fraction (HFrEF)
WHAT IS NEW?
• Observations that describe the association between obesity and heart failure (HF) have rarely accounted for the changes in lean body mass with aging. • This analysis of healthy older adults over 6 years shows that in those who newly develop HF, a striking loss of lean body mass occurs, particularly among men, to a greater extent than aging generally imparts, despite increases in obesity.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Loss of lean mass in older HF patients likely increases their risks of physical functional decline, falls, and frailty.
• HF management should broaden to include greater emphasis on nutrition and other approaches to preserve lean mass as a potential novel target in HF therapy.
• More research regarding body composition and sex differences in the aging process, and their relationship to HF pathophysiology, may provide novel therapeutic approaches. 
Dual-Energy X-Ray Absorptiometry
Lean mass of the upper and lower extremities and the total body was assessed using DXA (Hologic Quad Data Rate 4500, software version 8.21; Waltham, MA). Bone mineral content was subtracted from the total and regional lean mass to define total nonbone lean mass, which represents primarily skeletal muscle in the extremities. 15 Fat mass was estimated for the whole body as well. Both the percent fat and total fat were examined in these analyses. Total body nonbone mass was also calculated. DXA scans were conducted yearly from baseline to the year 6 visit (ie, 5-year follow-up).
Body weight and height were measured by calibrated balance beam scale and stadiometer with all participants restricted to light clothing and no shoes. BMI was calculated as body weight (kg) divided by the square of height in meters. Three weight change groups were also determined: stable (<3% change), gainers (≥3% increase), and losers (≥3% decrease). 
Potential Confounders
Potential confounders known to be associated with weight loss, muscle loss, or HF included baseline age, self-reported race, sex, baseline prevalent chronic conditions, and baseline physical activity (kilocalories per week, as assessed by walking/exercise/recreational activities/chores determined by questionnaire 16 ). Chronic obstructive pulmonary disease was defined as self-reported physician diagnosis of chronic bronchitis, emphysema, or asthma. Hypertension was defined as self-report of physician diagnosis, confirmed by the use of an antihypertensive medication and presenting with a systolic blood pressure of ≥140 mm Hg at the baseline clinic visit. Diabetes mellitus was defined as self-report of physician diagnosis confirmed by the use of diabetic medication, or fasting blood glucose ≥126 mg/dL, or plasma glucose levels ≥200 mg/dL after an oral glucose tolerance test. Stroke and coronary heart disease (including myocardial infarction, percutaneous or surgical revascularization, or angina) were adjudicated using medical records. Chronic kidney disease was defined as having an estimated glomerular filtration rate<60 mL/min per 1.73 m 2 , which was estimated using serum creatinine and the 4-variable modification of diet in renal disease equation. 17 Depression was defined as a score of ≥10 on the modified Center for Epidemiological Studies-Depression Scale. 18 Cognition was assessed using the Modified Mini-Mental State Examination score and mild cognitive impairment was defined as a score of <80. 19 Multimorbidity was defined as the number of prevalent chronic conditions (chronic obstructive pulmonary disease, hypertension, diabetes mellitus, stroke, coronary heart disease, chronic kidney disease, depression, and cognitive impairment).
Statistical Analyses
Baseline means and SDs or frequencies and percentages were calculated stratified by sex and incident HF status. Baseline levels were compared between men and women and HF cases and controls within sex-strata using t tests and χ 2 tests as appropriate. A P<0.05 was considered significant. When referring to baseline in this article, we are referring to the initial Health ABC visit. Health ABC is a prospective cohort study of 3075 nondisabled black (41.7%) and white men and women (51.5%) aged 70 to 79 years, enrolled from March 1997 to April 1998. Of the 3075 enrolled, 2815 participants had both a baseline dual-energy x-ray absorptiometry (DXA) scan and either a follow-up DXA scan (controls, n=2704) or a DXA scan after incident heart failure (HF; cases, n=111).
The primary exposure was incident HF with body composition changes in each compartment from DXA as dependent variables. Separate mixed-effects random slopes and intercepts models for each body composition measure were used to examine the rates of body composition change after incident HF compared with controls and to the period before HF. The time from incident HF to follow-up DXA scans was based on the hospital admission date. For ease of interpretation, days to HF and days between clinic visits were converted to years by dividing by 365.25. The primary predictor in each model was the estimated β coefficient corresponding to the interaction term of time by incident HF, where the time was between the date of the first HF hospitalization and the follow-up DXA scan. These estimated βs represent the yearly rate of change in body composition (g/y) after incident HF compared with non-HF and the period before HF. The interaction term accounts for the fact that an incident HF event could have occurred at any time between yearly DXA scans by factoring in the exact amount of time between the incident HF event and each subsequent follow-up DXA scan. In other words, in the models, starting DXA values in controls were based on the initial Health ABC study scans and starting DXA values for cases were based on the most recent yearly scan before the incident HF event. Time 0 for controls was study entry and time 0 for cases was the date of first HF hospitalization, which accounts for differences in the time between the HF event and subsequent DXAs.
No adjustments were made for multiple testing, as these were hypothesis-driven analyses addressing a priori research questions. Nonetheless, type I error may be inflated as a result.
To determine whether the amount of lean or fat mass change was excessive after HF for a given amount of total body mass change, data were also adjusted for the annualized rate of total body mass change (from DXA), which was calculated from linear regression using all available time points (baseline to the year 6). To illustrate absolute body composition changes between HF and non-HF, absolute yearly changes were estimated by solving the mixed-effects model. Furthermore, to clarify whether body composition changes were excessive for a given change in total mass, absolute body composition changes were also indexed to the average yearly total mass change of a HF case (−802.9 g/y for men and −841.0 g/y for women).
Because of significant interactions between overall weight change directions, models pertaining to weight losers, gainers, and those who were stable in weight were all assessed separately. ) and lean body mass were analyzed. Finally, subgroups (HFpEF versus HFrEF) were each compared. In all analyses, men and women were examined separately as factors associated with body composition change differ by sex. 6 Simulations using artificially generated data sets where the rate of lean, fat, and total mass before and after HF was known were used to confirm the accuracy of all models, and all analyses were conducted using SAS v9.3 (Cary, NC).
RESULTS
Mean age of the Health ABC study population was 73.6±2.9 years and included 48.5% men and 59.6% whites. Baseline characteristics of the Health ABC study population are listed in Table I in the Data Supplement. Relatively more women than men had hypertension and depression, and relatively more men than women had coronary heart disease, diabetes mellitus, and cognitive impairment. Incident HF occurred in only 3.9% of the overall population, with similar rates in men and women. Table 1 shows baseline (entry into Health ABC) characteristics of the Health ABC study population, focusing on comparisons between those who developed incident HF and those who did not, and also subdivided by sex. Men and women with HF had relatively greater comorbidity at baseline than those without HF, but comorbidity was also relatively low in both groups. Among men with HF, there were 2.0 (interquartile range, 1-3) other comorbid health conditions versus 1.4 (interquartile range, 0-2) in men without HF. Among women with HF, there were 1.9 (interquartile range, 1-3) total comorbid health conditions versus 1.3 (interquartile range, 0-2) in women without HF. Coronary heart disease at baseline was more common in men and women with HF than in those with the non-HF. Diabetes mellitus was more frequent in men with HF than in those without HF. Among women, stroke and chronic obstructive pulmonary disease were more common among women with HF than among those without HF. DXA measurements were assessed at baseline and repeated annually for 5 years. Starting DXA values for controls was study entry and the DXA immediately before to HF for cases. Each subsequent DXA was used to calculate rate of change. Time 0 for controls was study entry and time 0 in cases was the date of first HF hospitalization, which accounts for differences in the time between the HF event and subsequent DXAs. Regression coefficients are for the interaction of HF×time and represent differences in yearly changes between cases and controls. DXA indicates dual-energy x-ray absorptiometry; HF, heart failure; and SE, standard error. *Model 1: adjusted for age, race, site, baseline: smoking, alcohol consumption, education, body mass index, hypertension, coronary heart disease, stroke, chronic obstructive pulmonary disease, diabetes mellitus, chronic kidney dysfunction, depression, low Teng Mini-Mental State Examination score, and physical activity main effects and time interactions in mixed models. †Model 2: Model 1 additionally adjusted for annualized rate of change in total body mass. ‡Random slopes and intercepts mixed model with total, lean, or fat mass or percent fat by time interaction as outcome. Table 2 shows baseline DXA measures of body composition, subdivided into HF and sex. Despite similar mean BMI in men and women, men had higher total mass, total lean body mass, and appendicular lean mass than women. In men, BMI and lean body mass were higher in those who developed incident HF. In women, BMI, total mass, lean body mass, and appendicular lean mass were all higher in those who developed HF. Table 3 and Figure 2A and 2B show the main results from models used to assess body composition changes in HF cases versus controls. Model 1 adjusts for confounders to examine whether participants who developed HF experienced absolute differences about body composition change. Model 2 adjusts additionally for annualized weight loss to assess whether those with HF experienced accelerated loss of lean or fat mass for a given weight change. As shown in Table 3 , total mass, lean mass, and appendicular lean mass all decreased more in those who developed incident HF than in those who did not, among both men and women (model 1). After adjusting for annualized weight loss, appendicular mass decline remained significant only in men. Among women, the loss of lean mass was largely explained by the annualized weight changes. Figure 2 depicts body composition changes calculated from the models described in Table 3 . In Figure 2Ai and 2Aii, loss of lean mass and annualized lean mass were significantly greater in those who developed HF than in those who did not among men, and loss of appendicular lean mass remained greater in those who developed HF than in those who did not develop HF even after adjusting for annualized changes. . Differences in total lean, appendicular lean, and total fat mass between the heart failure (HF) vs non-HF groups.* A, Male participants in the HF group developed significantly greater losses in total lean mass and appendicular lean mass over time compared with men in the non-HF group. When data are indexed to annual changes of total mass per year, the loss of appendicular lean mass associated with HF vs non-HF remained significant. Total fat mass decreased in the HF and non-HF groups before and after annualized weight changes were considered with no significant differences between the groups. B, Female participants in the HF group also developed greater losses of total lean mass and appendicular lean mass compared with women in the non-HF group. However, once annualized weight changes were considered, the loss of total lean mass and appendicular lean mass were no longer greater among those with HF. Total fat mass decreased in the HF and non-HF groups before and after annualized weight changes were considered with no significant differences between the groups. *Starting dual-energy xray absorptiometry (DXA) values in controls were based on the initial Health, Aging, and Body Composition study scans and starting DXA values for cases were based on the most recent yearly scan before the incident HF event. Time 0 for controls was study entry and time 0 in cases was the date of first HF hospitalization, which accounts for differences in the time between the HF event and subsequent DXAs.
Although Figure 2Bi and 2Bii suggests similar relationships between lean mass and appendicular lean mass in women with HF, the loss of lean mass and appendicular lean were no longer significant compared with the women who did not develop HF after accounting for annualized weight changes. Similarly, among women with stable or gains in weight, relatively proportions of lean (total or appendicular) or fat mass did not change significantly. Table 3 and Figure 2Aiii and 2Biii focus on body fat, which decreased similarly in participants with and without HF. Among the men who developed HF, 11 were normal weight, 23 were overweight, and 18 were obese.
We conducted several subgroup analyses, testing for whether baseline BMI, the direction of weight change (gain versus loss), or the type of HF (HFrEF versus HFpEF) influenced the degree of lean loss. No significant interactions were evident between baseline BMI category and loss of lean mass after development of HF in men (P=0.98) or women (P=0.36), suggesting that loss of lean is similar across BMI categories. Within weight change categories, only men who lost weight manifested differences between those who developed HF and those who did not develop HF, that is, participants who developed HF lost a higher proportion of lean mass. Relative losses of lean (total or appendicular) or fat mass among women with HF were not similarly significant (Table 4) . Finally, associations between HF and lean mass tend to be stronger in HFrEF than in HFpEF (Table II in the Data Supplement). However, in the women who developed HFpEF increases in fat mass and percent fat mass change persisted, even after accounting for annualized changes in weight. Although such of sex-related changes in fat in HFpEF are intriguing, the small number of HFpEF limits decisive conclusions.
DISCUSSION
In this study, we studied participants in Health ABC and showed greater losses of lean body mass in older men and women who developed HF and lost weight com- DXA measurements were assessed at baseline and repeated annually for 5 years. Starting DXA values for controls was study entry and the DXA immediately before HF for cases. Each subsequent DXA was used to calculate rate of change. Time 0 for controls was study entry and time 0 in cases was the date of first HF hospitalization, which accounts for differences in the time between the HF event and subsequent DXAs. Time is from the first HF hospitalization in the incident HF group. Weight change groups were defined by the following criteria: stable (<3% change), gainers (≥3% increase), and losers (≥3% decrease). Regression coefficients are for the interaction of HF×time and represent differences in yearly changes between cases and controls. DXA indicates dual-energy x-ray absorptiometry; HF, heart failure; and SE, standard error. *Model 1: adjusted for age, race, site, baseline: smoking, alcohol consumption, education, body mass index, hypertension, coronary heart disease, stroke, chronic obstructive pulmonary disease, diabetes mellitus, chronic kidney dysfunction, depression, low Teng mini mental score, and physical activity main effects and time interactions in mixed models. †Model 2: Model 1 additionally adjusted for annualized rate of change in total body mass. ‡Random slopes and intercepts mixed model with total, lean, or fat mass or percent fat by time interaction as outcome.
pared with those without HF. Notably, loss of appendicular lean tissue remained significant in men even after accounting for annualized weight change, which implies that HF accelerates appendicular lean tissue atrophy beyond that associated with typical aging. Although lean change after HF in women tracked well with total weight loss, it still notable that women with HF lost more lean and total weight than controls. These changes were most pronounced in men and women with HF who were losing overall body weight in this time period. Clinical implications of lean tissue loss are substantial; diminished lean mass is associated with increased mortality, 20, 21 functional decline, weakening, frailty, disability, diminished quality of life, altered pharmacokinetics and dynamics, increased risks of falls, and many other harmful sequelae. 8, 9 In particular, loss of appendicular lean mass corresponds to poor clinical prognosis. 22 The implications of these data are intensified by the high prevalence of HF among older adults. HF is endemic among today's expanding population of senior adults, 5 and prognosis (mortality, morbidity, and quality of life) worsens with age. 23, 24 Whereas contemporary treatment standards remain oriented primarily to central pathophysiology, the accelerated lean body tissue loss has substantial bearing on outcome but is rarely addressed as part of routine care.
Just as with men, loss of lean tissue was greater in women with HF than in those without but was largely explained by greater annualized weight loss. These patterns are consistent with studies, including Health ABC, demonstrating greater lean body mass in men than in women during youth, but relatively greater atrophy of lean mass in men than in women with aging. 6, 25 Women have relatively less lean mass, but it is better conserved with age. Bazzocchi et al 26 describe greater stability of lean mass in healthy women versus men, suggesting that there is a natural protective capacity in women with normal aging, which also seems to moderate the added atrophying effects of disease in old age. Ongoing study aims to uncover biological mechanisms underlying sex differences.
High BMI at baseline (entry into Health ABC) was associated with subsequent incident HF. However, in contrast to many studies that rely on BMI or other anatomic measurements to assess body composition using DXA, data revealed loss of lean tissue over time and with relatively preserved fat mass and perhaps even increased fat mass in women with HFpEF. High BMI seems to mask the loss of lean tissue and the shift toward sarcopenic obesity. 27 Therefore, it seems consistent that we did not detect an interaction between BMI category and lean body mass change in those who developed HF, refuting the premise of a beneficial obesity paradox. Nonetheless, the small number of HF cases limits any definitive conclusions.
Physical challenges associated with fat mass escalate as underlying skeletal muscle mass decreases. The relatively higher proportion of fat mass is also conducive to greater inflammation 28 (ie, accelerating atrophy) and lower muscle quality 29 (ie, increasing infiltrative fat) and seem likely to exacerbate risks of mortality and disability.
Frailty is commonly described as a phenotype that includes diminished physical activity, weakness, slowing, and exhaustion. 30 It is highly prevalent in older adults with HF 31, 32 and correlates strongly with increased risks of disability and dependency. 33 The loss of lean mass with aging and HF also seems related to frailty 34 and reinforces the rationale to target body composition in HF management. Ongoing studies are exploring the relationship between frailty and HF and the potential benefits of diet, exercise, and other interventions. [35] [36] [37] [38] Strength training may have particular utility. 39, 40 Future analyses in Health ABC will aim to determine the impact of HF on physical performance and whether body composition changes mediate any effect.
The associations of HF with respect to body composition were more apparent in HFrEF than in HFpEF. In many respects, this seems counterintuitive as HFpEF includes degenerative effects on skeletal muscle that parallel those in HFrEF. 2, 41 Recent literature highlights the constitutive changes in body composition with related cellular and subcellular changes that occur with HFpEF. 42 Other studies highlight that the dominant role inflammation plays in HFpEF pathophysiology, 43 which may compound risk of lean tissue loss. The differences in body composition, HFpEF versus HFrEF, in this analysis may merely reflect insufficient statistical power to assess HFpEF reliably, but they may also indicate that changes in lean mass associated with HFpEF may occur much earlier (ie, long before onset of prototypical HF symptoms and signs), and may be largely complete before the time period of Health ABC's assessments. Additional studies are needed with larger HFpEF populations to better clarify prognostic implications of body composition changes.
Strengths of this study relate to the distinctions of Health ABC. HF was assessed with careful, adjudicated assessments with clear delineation of disease onset, and body composition was serially ascertained using DXA. Further, we had exact time to event data and the models were able to take into account the number of days between the HF event and subsequent DXA scans. The analysis also stands out for assessing changes in lean mass associated with disease relative to annualized weight loss, which allowed us to determine whether body composition changes were disproportionate for a given weight change.
Weaknesses of these analyses include its relatively small sample of HF cases, and particularly few with HFpEF. Moreover, HF was based only on hospital diagnoses. Although this can be construed as a strength as it ensures standardized accuracy, it is possible that adults diagnosed with HF as outpatients were not included. This may be particularly true among those with HFpEF. Health ABC also enrolled relatively healthy older adults at baseline, who developed HF amid little comorbid-ity, limiting generalizability to older HF populations in which multimorbidity is endemic.
Summary
Overall, this study highlights the impact of HF on changes in body composition. Specifically, we showed greater loss of lean mass after HF compared with non-HF controls. In men, we show an accelerated loss of lean mass after HF for a given weight change, whereas lean loss tracked more closely with overall weight change in women who developed HF. Lean mass is a known determinant of health, and loss of lean mass is particularly dangerous in HF as it has bearing on functional degradation as well as frailty. This study provides strong rationale for future studies that delineate the mechanisms underlying reduced lean mass, with relative differences in respect to sex. Inflammation, adipokines and other key factors may determine these relationships. Moreover, opportunities for therapeutic enhancement also seem likely, with diet, novel medications, and exercise all likely candidates for improved care and outcomes. 
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